pH modulation using CsCl enhances therapeutic effects of vitamin D in LNCaP tumor bearing mice

Prostate

Volumn 64, Issue 3, 2005, Pages 316-322

  Guns, Emma S ^a   Xie, Xiaowei ^a   Fedoruk, Matthew ^a   Madera, Candice ^a   Cowell, Simon ^a   Mayer, Lawrence D ^b   Skov, Kirsten ^b   Gleave, Martin E ^a   Kozlowski, Piotr ^a  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

Cesium chloride; LNCaP tumor; MDA LCC6 tumor; MRS; pH; Prostate cancer; Vitamin D

Indexed keywords

CESIUM CHLORIDE; PROSTATE SPECIFIC ANTIGEN; VITAMIN D; VITAMIN D RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CANCER INHIBITION; CELL PH; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG EFFECT; DRUG SENSITIZATION; FEMALE; HUMAN; HUMAN CELL; LEG MUSCLE; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PH MEASUREMENT; PRIORITY JOURNAL; PROSTATE CANCER; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

ANIMALS; CELL LINE, TUMOR; CESIUM; CHLORIDES; DNA-BINDING PROTEINS; DRUG SYNERGISM; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MICE; MICE, MUTANT STRAINS; MICE, NUDE; NUCLEAR PROTEINS; PROSTATIC NEOPLASMS; SPECTROPHOTOMETRY, ATOMIC; TISSUE DISTRIBUTION; VITAMIN D; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 22144492611     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20257     Document Type: Article

References (21)

1. Bhujwalla ZM, A.D., Aboagye E, Ackerstaff E, Gillies RJ, Natarajan K, Solaiyappan M. The physiological environment in cancer vascularization, invasion and metastasis. Novartis Found Symp 2001;240:23-38; Discussion 38-45, 152-153.
2. Brooks SE, G.X., Kaufmann PM, Marcus DM, Caldwell RB. Modulation of VEGF production by pH and glucose in retinal Muller cells. Curr Eye Res 1998;17(9):875-882.
3. Simon S. The multiple mechanisms of multidrug resistance and cellular pH. Novartis Found Symp 2001;240:269-281; Discussion 282-289.
4. Negri-Cesi P, P.A., Colciago A, Magni P, Martini P, Motta M. Presence of 5alpha-reductase isozymes and aromatase in human prostate cancer cells and in benign prostate hyperplastic tissue. Prostate 1998;34(4):283-291.
5. Forsten KE, A.R., San Antonio JD. Insulin-like growth factor (IGF) binding protein-3 regulation of IGF-I is altered in an acidic extracellular environment. J Cell Physiol 2001;189(3):356-365.
6. Hochgrebe T, P.G., Wilce J, Easterbrook-Smith SB. pH-dependent changes in the in vitro ligand-binding properties and structure of human clusterin. Biochemistry 2000;39(6):1411-1419.
7. Brizel DM, S.T., Scher RL, Walenta S, Clough RW, Dewhirst MW, Mueller-Klieser W. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;51(2):349-353.
8. Raghunand N, G.R. pH and chemotherapy. Novartis Found Symp 2001;240:199-211; Discussion 265-268.
9. Seligson AL, T.R., Bressi JC, Douglass JG III, Sovak M. A new prodrug of paclitaxel: Synthesis of Protaxel. Anticancer Drugs 2001;12(4):305-313.
10. Raghunand N, H.X., van Sluis R, Mahoney B, Baggett B, Taylor CW, Paine-Murrieta G, Roe D, Bhujwalla ZM, Gillies RJ. Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer 1999;80(7):1005-1011.
11. Tannock IF, R.D. Acid pH in tumors its potential for therapeutic exploitation. Cancer Res 1989;49:4373-4384.
12. Yamagata M, H.K., Stamato T, Tannock IF. The contribution of lactic acid to acidification of tumours: Studies of variant cells lacking lactate dehydrogenase. Br J Cancer 1998;77(11):1726-1731.
13. Newell K, F.A., Pouyssegur J, Tannock I. Studies with glycolysis-deficient cells suggest that production of lactic acid is not the only cause of tumor acidity. Proc Natl Acad Sci 1993;90:1127-1131.
14. 31P magnetic resonance spectroscopy. Biochem Pharmacol 1999;57:309-312.
15. Nagpal S, L.J., Boehm MF. Vitamin D analogs: Mechanism of action and therapeutic applications. Curr Med Chem 2001;8(13): 1679-1697.
16. Tuohimaa P, L.A., Aksenov N, Pennanen P, Syvala H, Lou YR, Ahonen M, Hasan T, Pasanen P, Blauer M, Manninen T, Miettinen S, Vilja P, Ylikomi T. Vitamin D and prostate cancer. J Steroid Biochem Mol Biol 2001;76(1-5):125-134.
17. Miller GJ. Vitamin D and prostate cancer: Biologic interactions and clinical potentials. Cancer Metastasis Rev 1999;17(4):353-360.
18. Hisatake J, O.K.J., Uskokovic MR, Tomoyasu S, Koeffler HP. Novel vitamin D(3) analog, 21-(3-methyl-3-hydroxy-butyl)-19-nor D(3), that modulates cell growth, differentiation, apoptosis, cell cycle, and induction of PTEN in leukemic cells. Blood 2001;97(8):2427-2433.
19. Gleave M, T.A., Miyake H, Brown B, Beraldi E, Goldie J. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 1999;5:1-8.
20. Hazav P, S.S., Moran A, Levy R. Involvement of intracellular pH elevation in the effect of 1,25-dihydroxyvitamin D3 on HL-60 cells. Cancer Res 1989;49(1):72-75.
21. Reddy GS, J.G., Kooh SW, Fraser D. Inhibition of 25-hydroxyvitamin D3-1-hydroxylase by chronic metabolic acidosis. Am J Physiol 1982;243(4):E265-E271.